Obesity and cardiovascular risk factors in rheumatoid arthritis [7]

Rheumatology

Volumn 45, Issue 6, 2006, Pages 782-

  Armstrong, D J ^a,b   McCausland, E M ^a,b   Quinn, A D ^b   Wright, G D ^a,b  

^a MUSGRAVE PARK HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LETTER; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDITERRANEAN DIET; OBESITY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; WEIGHT REDUCTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; OBESITY; RISK FACTORS;

EID: 33745632628     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel124     Document Type: Letter

References (3)

1. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: Two sides of the same coin? Rheumatology 2005;44: 1473-82.
2. Liu S, Manson JAE. What is the optimal weight for cardiovascular health? Br Med J 2001;322:631-2.
3. National Institute for Clinical Excellence. Technology Appraisal Guidance - No. 22 Guidance on the Use of Orlistat for the Treatment of Obesity in Adults. March 2001.